Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Study design Phase 2, double blinded, single-center, 1:1 randomized clinical trial of Chloroquine vs Chloroquine/losartan for the treatment of SARS-CoV-2 pneumonia in non-critically ill subjects
Description: Determine all-cause mortality up to 28 days after randomization of Chloroquine Phosphate Compared to Chloroquine Phosphate plus Losartan in Non-Critically Ill Patients with SARS-CoV-2 Pneumonia.
Measure: Overall mortality Time: 28 daysDescription: Compare the clinical outcome of Chloroquine Phosphate treatment vs Chloroquine Phosphate plus Losartan in the follow-up visit at the end of treatment. Acording to NIH and FDA definitions
Measure: Clinical outcome assessment Time: 28 daysDescription: Assess the adverse events associated to chloroquine and chloroquine plus losartan at 28 days
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Time: 28 daysDescription: Time to negative Polymerase chain reaction (PCR) test from baseline: testing every 48hrs until a negative result
Measure: Time to negative SARS-CoV-2 test Time: 28 days